Aspire Biopharma Holdings (ASBP) Total Debt (2023 - 2026)

Aspire Biopharma Holdings (ASBP) has 4 years of Total Debt data on file, last reported at $499214.0 in Q1 2026.

• On a quarterly basis, Total Debt changed 0.0% year-over-year to $499214.0 in Q1 2026; TTM through Mar 2026 was $499214.0, a 0.0% change from a year earlier, with the FY2025 full-year figure at $2.8 million, down 31.66% from the prior year.
• Total Debt for Q1 2026 stood at $499214.0, down from $2.8 million in the prior quarter.
• Over the last five years, Total Debt for ASBP reached as high as $5.3 million in Q3 2024 and fell as low as $24768.0 in Q4 2023.
• Historically, Total Debt has averaged $2.0 million across 4 years, with a median of $677395.0 in 2024.
• Across the five-year window, Total Debt soared 16385.91% in 2024 and sank 41.65% in 2025, its largest moves.
• Year by year, Total Debt stood at $24768.0 in 2023, then surged by 16385.91% to $4.1 million in 2024, then plunged by 31.66% to $2.8 million in 2025, then plunged by 82.11% to $499214.0 in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $499214.0 in Q1 2026, $2.8 million in Q4 2025, and $4.7 million in Q3 2025.